More frozen cells are lost in the four minutes after they leave the freezer than in the entire time they spent in it. Thawing is the step protocols describe in one line and reviewers never question, and it is where a well-frozen lot becomes a disappointing one.
Why speed matters on the way up
Freezing is done slowly on purpose. Thawing should be done quickly, for a reason that is the mirror image of the freezing logic. As a sample warms through the intermediate temperature range, small ice crystals become thermodynamically unstable and reorganise into larger ones. That recrystallisation is destructive, and the longer a sample lingers in that range the more of it occurs.
Which is why the standard instruction is a rapid warm in a bath at physiological temperature until only a small ice crystal remains, then straight into the next step. Warming a vial slowly at the bench is the single most damaging thing routinely done to cryopreserved cells.
Dilute gradually, not generously
The cells coming out of that vial are sitting in a high concentration of cryoprotectant, and they have equilibrated to it. Adding a large volume of medium in one go creates an osmotic gradient that pulls water in faster than the cell can accommodate, and cells that survived the freeze are lost at this step instead.
Adding medium dropwise at first, then more quickly, gives the cell time to adjust. It takes a minute longer and it is the difference between a good recovery figure and an unexplained one.
The rest period, and why skipping it is a false economy
Thawed cells are not ready to assay. The ones that did not survive are still in the tube, releasing DNA and debris that clumps the preparation and traps viable cells with it. The ones that did survive are carrying damage and have not resumed normal function.
A rest in culture, commonly overnight, lets dying cells complete the process so they can be removed, and lets survivors recover. It is skipped constantly, usually because a protocol was written around fresh material and the material later changed. When a frozen lot appears to underperform against a fresh one, the rest period is the first thing to check and it is more often the explanation than the lot.
Related product
Cryopreserved PBMCs. Single-donor PBMCs in current catalogue formats, with the donor record attached.
Where recovery is lost
| Step | What goes wrong | Fix |
|---|---|---|
| Warming | Slow warm allows ice recrystallisation | Rapid warm, remove while a small ice crystal remains |
| Dilution | Osmotic shock from adding medium too fast | Dropwise at first, then increase |
| Cryoprotectant removal | Prolonged exposure at warm temperature | Dilute or wash promptly, keep the sequence tight |
| Centrifugation | Aggressive spin on fragile cells | Gentler conditions than for fresh material |
| Clumping | Released DNA traps viable cells | DNase where appropriate, and do not fight clumps mechanically |
| Counting | Debris inflates automated counts | Count after rest, and pair count with viability |
Count at the right moment
A count taken immediately post-thaw includes debris and cells that are alive at that instant and will not be alive in two hours. It overstates what you have. Counting after the rest period, paired with a viability measurement taken at the same time, gives a number you can plan an experiment against.
This also makes recovery figures comparable between lots and between operators, which they are not when the timing of the count varies.
What to expect from well-handled material
Published specifications describe what the supplier stands behind at a defined timepoint rather than what you will observe after your own handling. OrganaBio lists post-thaw viability at 85% or above on peripheral blood NK cells, and viability and CD56+ purity each at 90% or above on cord blood NK cells. The gap between a published figure and a bench observation is usually the thaw, which makes it worth controlling before it becomes a supplier conversation.
Freezing mechanics are covered in cryopreserving PBMCs, and the format decision in the fresh versus cryopreserved guide.
Frequently asked questions
Why should PBMCs be thawed quickly?
Because small ice crystals become unstable as a sample warms through the intermediate temperature range and reorganise into larger, more destructive ones. The longer a sample lingers in that range, the more recrystallisation damage occurs.
Why add medium dropwise after thawing?
Cells emerging from the vial have equilibrated to a high cryoprotectant concentration. Adding a large volume at once creates an osmotic gradient that pulls water in faster than the cell can accommodate, so cells that survived the freeze are lost during dilution instead.
Do I need to rest PBMCs after thawing?
For most functional work, yes. Cells that did not survive release DNA and debris that clumps the preparation and traps viable cells, and survivors need time to recover function. Running an assay immediately post-thaw is defensible as a deliberate choice and problematic as an inherited habit.
When should I count thawed cells?
After the rest period, paired with a viability measurement taken at the same time. A count taken immediately post-thaw includes debris and cells that will not survive the next couple of hours, so it overstates what you have.
Why do my viability figures differ from the supplier’s specification?
A published specification describes what the supplier stands behind at a defined timepoint, not what you observe after your own handling. The gap is usually the thaw, which is worth controlling before it becomes a supplier conversation.
Should thawed cells be centrifuged the same way as fresh cells?
No. Freshly thawed cells are fragile and benefit from gentler conditions than the same protocol would apply to fresh material. Aggressive spinning at this point costs recovery.
How do I handle clumping after thaw?
Clumping comes from DNA released by dying cells, so a DNase step addresses the cause. Trying to break clumps mechanically damages the viable cells caught inside them.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
